Skip to content

Restore EF Observational Study

Restore EF Observational Study (in High-risk PCI)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04648306
Enrollment
406
Registered
2020-12-01
Start date
2019-09-01
Completion date
2021-09-30
Last updated
2021-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina, Stable, Coronary Artery Disease, NSTEMI - Non-ST Segment Elevation MI, Unstable Angina

Keywords

Impella, Hemodynamic Mechanical Support, Left ventricular ejection fraction, Surgical turndown, High Risk PCI

Brief summary

A multi-center, prospective, observational, non-interventional single arm, study of the intermediate-term clinical outcomes collected from electronic health records of high-risk patients which have previously undergone standard of care prophylactic Impella support for a non-emergent percutaneous coronary intervention (PCI).

Detailed description

1. Hypothesis The prophylactic use of Impella 2.5 or CP heart pumps during a non-emergent PCI in hemodynamically stable patients at high-risk for periprocedural complications during the procedure is associated with a significant improvement in the patient's LVEF and clinical status (heart failure symptoms and hospital readmissions) in the intermediate-term follow-up period post-ProPCI 2. Objectives The primary objective of this study is to assess the patient's LVEF at 90 days post-ProPCI (60 to 180 days window) as assessed in routine clinical practice and collected from EHR by clinical investigators. The secondary objective of the study is to assess the potential association between the completeness of revascularization and the clinical status at 90 days post-ProPCI (60-180 days window). Clinical status includes NYHA heart failure functional class and hospital readmission. 3. Sample Size: The study will enroll more than 1,000 patients at up to 30 investigational sites with experienced Impella operators (≥ 25 cases). 4. Primary Endpoint: Subject's LVEF at 90 days post-ProPCI (60 to 180 days window) collected from the subject's EHR. 5. Secondary Endpoints: * Completeness and extent of revascularization * NYHA functional class at 90 days post-ProPCI (60 to 180 days window) * Readmission at 90 days post-ProPCI (60 to 180 days window)

Interventions

DEVICEProphylactic Impella support for a non-emergent PCI

Impella percutaneous mechanical circulatory support is placed via the femoral or axillary artery prior to a non-emergent PCI in patients at high risk for periprocedural complications including hemodynamic collapse.

Sponsors

Abiomed Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Subject has previously undergone (≥ 60 days) an Impella Protected PCI (ProPCI) at a study site as identified in the Impella quality (IQ) assurance database (patients who expired or were lost to follow-up prior to opening of the follow-up study window (day 60 post Impella protected PCI) will not be included in the study

Exclusion criteria

* Subject with cardiogenic shock at the time of Impella insertion. Cardiogenic shock defined as: systemic hypotension (systolic blood pressure (SBP) \<90 mmHg or the need for inotropes/pressors to maintain a SBP \>90mmHg) * Subject with ST elevation myocardial infarction at the time of Impella insertion. * Subject underwent coronary bypass surgery after the index Impella ProPCI * Subject underwent repeat revascularization with PCI after the index Impella ProPCI * Subject underwent other cardiac procedures including valve therapies (surgical or percutaneous) after the index Impella ProPCI * Subject underwent cardiac resynchronization therapy (CRT) initiated after the index Impella ProPCI * Any known medical condition with a life expectancy \<6 months

Design outcomes

Primary

MeasureTime frameDescription
Left ventricular ejection fraction (LVEF)90 days post Protective PCI (60 to 180 days window)Left ventricular ejection fraction (LVEF) %

Secondary

MeasureTime frameDescription
Survival Rate90 days post Protected PCI (60 to 180 days window)Survival rate post non-emergent percutaneous coronary intervention (ProPCI)
NYHA Functional Class90 days post Protected PCI (60 to 180 days window)New York Heart Association (NYHA) functional class
Readmission90 days post Protected PCI (60 to 180 days window)Readmission post non-emergent percutaneous coronary intervention (ProPCI)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026